ARTICLE | Company News

3-Dimensional, Boehringer Ingelheim Pharmaceuticals Inc. deal

March 13, 2000 8:00 AM UTC

3-D will use its DirectedDiversity combinatorial chemistry to identify compounds active against targets selected by Boehringer Ingelheim. 3-D will receive an upfront technology access fee, R&D funding, milestones and royalties. Boehringer Ingelheim is responsible for development of selected compounds. ...